APA (7th ed.) Citation

Chiu, T., Huang, T., Chien, C., Huang, W., & Li, S. (2024). Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma. World journal of surgical oncology, 22(1), 242-11. https://doi.org/10.1186/s12957-024-03522-2

Chicago Style (17th ed.) Citation

Chiu, Tai-Jan, Tai-Lin Huang, Chih-Yen Chien, Wan-Ting Huang, and Shau-Hsuan Li. "Hypoalbuminemia and Hypercalcemia Are Independently Associated with Poor Treatment Outcomes of Anti-PD-1 Immune Checkpoint Inhibitors in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma." World Journal of Surgical Oncology 22, no. 1 (2024): 242-11. https://doi.org/10.1186/s12957-024-03522-2.

MLA (9th ed.) Citation

Chiu, Tai-Jan, et al. "Hypoalbuminemia and Hypercalcemia Are Independently Associated with Poor Treatment Outcomes of Anti-PD-1 Immune Checkpoint Inhibitors in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma." World Journal of Surgical Oncology, vol. 22, no. 1, 2024, pp. 242-11, https://doi.org/10.1186/s12957-024-03522-2.